<SEC-DOCUMENT>0001013762-21-000150.txt : 20211209
<SEC-HEADER>0001013762-21-000150.hdr.sgml : 20211209
<ACCEPTANCE-DATETIME>20211004183733
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001013762-21-000150
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20211004

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Bluejay Diagnostics, Inc.
		CENTRAL INDEX KEY:			0001704287
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				473552922
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		360 MASSACHUSETTS AVENUE, SUITE 203
		CITY:			ACTON
		STATE:			MA
		ZIP:			01720
		BUSINESS PHONE:		(978) 631-0152

	MAIL ADDRESS:	
		STREET 1:		360 MASSACHUSETTS AVENUE, SUITE 203
		CITY:			ACTON
		STATE:			MA
		ZIP:			01720
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 70%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<IMG SRC="img_001.jpg" ALT="Text&#10;&#10;Description automatically generated" STYLE="height: 73px; width: 150px"></FONT></TD>
    <TD ROWSPAN="2" STYLE="width: 30%; font-size: 10pt"><P STYLE="text-align: left; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100
                                            N. 18<SUP>th</SUP> Street</FONT></P>
                                                        <P STYLE="text-align: left; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Suite
                                            300</FONT></P>
                                                        <P STYLE="text-align: left; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Philadelphia,
                                            PA 19103</FONT></P>
                                                        <P STYLE="text-align: left; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>t
                                            </I><FONT STYLE="font-variant: small-caps">202.778.6400</FONT></FONT></P>
                                                        <P STYLE="text-align: left; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>f
                                            </I><FONT STYLE="font-variant: small-caps">202.778.6460 </FONT></FONT></P>
                                                        <P STYLE="text-align: left; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">www.schiffhardin.com
                                            &nbsp;</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Cavas
        S. Pavri</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">202.724.6847</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cpavri@schiffhardin.com</FONT></P></TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">October 4, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B><U>By EDGAR Submission</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Division of Corporation Finance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Office of Real Estate &amp; Construction&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">100 F Street, N.E.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">Re:</TD><TD>Bluejay Diagnostics, Inc.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">Amendment No. 1 to Draft Registration Statement
on Form S-1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">Submitted September 8, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">CIK No. 0001704287</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This letter is being submitted
on behalf of Bluejay Diagnostics, Inc. (the &ldquo;<U>Company</U>&rdquo;) in response to the comment letter, dated September 24, 2021,
of the staff of the Division of Corporation Finance (the &ldquo;<U>Staff</U>&rdquo;) of the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;)
with respect to the Company&rsquo;s Amendment No. 1 to its Draft Registration Statement on Form S-1 submitted September 8, 2021 (the &ldquo;<U>Draft
Registration Statement</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&rsquo;s Form S-1
Registration Statement (the &ldquo;<U>Registration Statement</U>&rdquo;) has been submitted to the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the Staff&rsquo;s convenience,
we have repeated the Staff&rsquo;s comment prior to the Company&rsquo;s response in bold italics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Amendment No. 1 to Draft Registration Statement on Form S-1 </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Prospectus Summary</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Our Company, page 2 </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>1. We
note your response to prior comment 4. Please revise to remove the statement that you could have potential FDA clearance in the fourth
quarter of 2022 as this statement is speculative. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Response</U>: The Registration
Statement has been revised to delete the above referenced statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Symphony Advantages, page
2</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B><I>2. </I></B></FONT><B><I>We
note your revised disclosure regarding the 2016 Japan study sponsored by Toray. Please revise to explain the significance of the chemiluminescent
enzyme immunoassay (CLEIA) method. For example, clarify whether this is the current standard or method for measuring serum IL-6 concentrations
in the blood</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Response</U>: The Company
has revised the referenced disclosure in the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Symphony IL-6, page 48</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B><I>3. </I></B></FONT><B><I>We
note your revised disclosure in response to prior comment 11. Please revise to clarify if you are conducting a single clinical study at
the University of Texas Southwestern Medical Center and Parkland Memorial Hospital or if these are separate clinical studies. For each
clinical study, please revise to disclose the study endpoints and the number of patients you plan to enroll. Please also disclose which
clinical studies are being conducted at William P. Clements Jr. University Hospital and Zale Lipshy Pavilion Hospital, when they began,
the number of patients and the study endpoints.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Response</U>: The Company
has revised the disclosure in the Registration Statement to address the Staff&rsquo;s comment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Intellectual Property, Proprietary Technology, page 50</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B><I>4. </I></B></FONT><B><I>We
note your revised disclosure in response to our prior comment 13. With respect your related patents in international territories, please
revise to disclose the type of patent protection granted for each technology such as composition of matter, use or process, and the patent
expiration dates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Response</U>: The Company
has revised the disclosure in the Registration Statement as follows (<I><U>emphasis added</U></I>):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;We do not currently
hold any patents directly. We rely on a combination either directly or through our license agreement with Toray of patent, copyright,
trade secret, trademark, confidentiality agreements, and contractual protection to establish and protect our proprietary rights. We have
licensed U.S. Patent Nos. 8,409,447 (&ldquo;the &rsquo;447 patent&rdquo;) and 8,821,813 (&ldquo;the &rsquo;813 patent&rdquo;). The &rsquo;447
patent is valid through at least February 2029 and is generally directed to a separation chip and a method for separating an insoluble
components from a suspension with the separation chip. The &rsquo;813 patent is valid through at least March 2028 and is generally directed
to a liquid-feeding chip, a liquid feeding method and analysis method. <I><U>We have also licensed use or process patents covering the
inventions and/or subject matter of the &rsquo;447 and &rsquo;813 patents in various international territories including Japan, Canada,
China, Europe and South Korea, which are valid through at least February 2027</U></I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Notes to Condensed Consolidated Financial Statements </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>2. Significant Accounting Policies, page F-26</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B><I>5. </I></B></FONT><B><I>On
page 37 you disclose the receipt of a $75,000 grant from the Massachusetts Growth Capital Corporation and we note that you recognized
the full amount for the period ended June 30, 2021. Please disclose your accounting policy for grants received.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Response</U>: The Company
has revised the disclosure in the Registration Statement to address the Staff&rsquo;s comment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">* * *</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Should you have any questions
regarding the foregoing, please do not hesitate to contact Cavas Pavri at (202) 724-6847.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%">Sincerely,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>SCHIFF HARDIN LLP</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">/s/ Cavas Pavri</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By: Cavas Pavri</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">Enclosures</TD><TD></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">cc:</TD><TD>Gordon Kinder, Chief Financial Officer</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>Ralph De Martino, Schiff Hardin LLP</TD></TR>
                                                                                                               </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>img_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !3 *H# 2(  A$! Q$!_\0
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MES*[UEK:\M'*UVDS]_7,]9/5W;6C<6W\+DOC<4E>I9<[>L5RW91113&%%%%
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M@W&TM)3C*27-4C*U1OJ^>SU;7,WRJ\KRM<Y7XZ?\'/\ JNB_L[:!\9_V9OV
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M_P +ZE-IE[!J.G2WV@Z_9W^EW<EAJ%M;WMF\]J[6]U!%/$4EC5A\V'_@G/\
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< "BBB@ HHHH *,#GWZ_RHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
